Managing Clinical Investigator Compensation

Managing Clinical Investigator Compensation provides easy and convenient access to the most up-to-date, detailed investigator compensation benchmarks.

- Use the data to build accurate and specific pay ranges.
- Compare your compensation rates to those of other companies and to investigators and improve cost controls.
- Understand the role of CROs in determining pay structure.
- Apply proven documentation and calculation strategies that will enable efficient negotiating and guarantee compliance.
- Keep up with the latest trends on investigator compensation.
- Learn why companies must be diligent and be proactive in recording payments they must take action before action is taken upon them.

This report brings significant knowledge and experience in researching the commercial Fair Market Value (FMV) arena.

The publisher has also conducted extensive research about clinical operations. To develop a comprehensive study, our analysts compiled survey data from investigators and companies across 13 therapeutic areas.

Please feel free to request free sample pages, or browse the table of contents from the tab above...

9 Executive Summary
12 Study Methodology
14 Study Definitions
15 Profiled Companies and Therapeutic Areas
16 Five Key Findings and Recommendations
25 Investigator Compensation in a Contricting Regulatory Environment
27 An FMV process: A Requirement Beyond Simple Cost Determinations
33 Contracting with Sites
39 Investigator Compensation: Industry Data
44 Developing Processes to Determine Investigator Compensation
58 Investigator Compensation Data
85 Investigator Compensation: Investigator Data

FIGURES AND GRAPHS

22 Figure E.1: Percentage of Data Sets per Therapeutic Area
Thought Leader Management Resources, Support and Activities
Thought Leader Management and MSL Structure and Staffing
34 Figure 1.1: Average Thought Leader Development Organizational Structure
35 Figure 1.2: Comparison of Thought Leader Development Organizational Structures
by Company Size
38 Figure 1.3: Company 44’s Thought Leader Development Team Reporting Structure
41 Figure 1.4: Percentage of Companies with a Dedicated Medical Science Liaison
(MSL) Department
41 Figure 1.5: Percentage of Companies with a Dedicated Medical Science Liaison
(MSL) Department
43 Figure 1.6: MSL Reporting Relationships by Department
44 Figure 1.7: Company Comparison: MSL Reporting Relationships
45 Figure 1.8: MSL Staffing Patterns from 2004 to 2006 to 2007
49 Figure 1.9: Thought Leader Management Staffing for 2007
50 Figure 1.10: Small Companies: Thought Leader Management Staffing for 2007
51 Figure 1.11: Mid-Sized Companies: Thought Leader Management Staffing for 2007
51 Figure 1.12: Large Companies: Thought Leader Management Staffing for 2007
52 Figure 1.13: Average Thought Leader Staffing for 2007
53 Figure 1.14: MSL Staffing for 2007
53 Figure 1.15: Small Companies: MSL Staffing for 2007
54 Figure 1.16: Mid-Sized Companies: MSL Staffing for 2007
54 Figure 1.17: Large Companies: MSL Staffing for 2007
55 Figure 1.18: Average MSL Staffing for 2007
Thought Leader Management Budgets
57 Figure 1.19: Rest-of-World Thought Leader Management Budgets for 2007
57 Figure 1.20: Average Thought Leader Rest-of-World Budgets for 2007
58 Figure 1.21: Small Companies: Thought Leader Management Rest-of-World Budgets for 2007
59 Figure 1.22: Mid-Sized Companies: Thought Leader Management Rest-of-World Budgets for 2007
59 Figure 1.23: Large Companies: Thought Leader Management Rest-of-World Budgets for 2007
52 Figure 2.12: Average Years of Experience Required by Medical Device
52 Primary Investigators by Phase
53 Figure 2.13: Percentage of Companies Whose Criteria for Primary Investigators
53 Include Published Articles
54 Figure 2.14: Average Number of Published Journal Articles Required of Primary
54 Investigators by Phase
55 Figure 2.15: Percentage of Companies Whose Criteria for Primary Investigators
55 Include Speeches
56 Figure 2.16: Percentage of Companies with Investigator Compensation Limits in Place
56 Investigator Compensation Data
59 Figure 2.17: Average Number of Total Site Fees by Phase
60 Figure 2.18: Average Number of Investigators Per Site by Phase
62 Figure 2.19: Average Primary Investigator Compensation by Phase
63 Figure 2.20: Autoimmune: Average Number of Total Site Fees by Phase
64 Figure 2.21: Autoimmune: Average Number of Investigators Per Site by Phase
64 Figure 2.22: Autoimmune: Average Primary Investigator Compensation by Phase
65 Figure 2.23: Cardio & Thrombosis: Average Number of Total Site Fees by Phase
65 Figure 2.24: Cardio & Thrombosis: Average Number of Investigators Per Site by Phase
66 Figure 2.25: Cardio & Thrombosis: Average Primary Investigator Compensation by Phase
66 Figure 2.26: CNS & Psychology: Average Number of Total Site Fees by Phase
67 Figure 2.27: CNS & Psychology: Average Number of Investigators Per Site by Phase
67 Figure 2.28: CNS & Psychology: Average Primary Investigator Compensation by Phase
68 Figure 2.29: Dermatology: Average Number of Total Site Fees by Phase
68 Figure 2.30: Dermatology: Average Number of Investigators Per Site by Phase
69 Figure 2.31: Dermatology: Average Primary Investigator Compensation by Phase
69 Figure 2.32: Endocrinology: Average Number of Total Site Fees by Phase
70 Figure 2.33: Endocrinology: Average Number of Investigators Per Site by Phase
70 Figure 2.34: Endocrinology: Average Primary Investigator Compensation by Phase
71 Figure 2.35: Gastroenterology: Average Number of Total Site Fees by Phase
71 Figure 2.36: Gastroenterology: Average Number of Investigators Per Site by Phase
72 Figure 2.37: Gastroenterology: Average Primary Investigator Compensation by Phase
72 Figure 2.38: Hematology: Average Number of Total Site Fees by Phase
73 Figure 2.39: Hematology: Average Number of Investigators Per Site by Phase
73 Figure 2.40: Hematology: Average Primary Investigator Compensation by Phase
74 Figure 2.41: Infectious Diseases: Average Number of Total Site Fees by Phase
74 Figure 2.42: Infectious Diseases: Average Number of Investigators Per Site by Phase
75 Figure 2.43: Infectious Diseases: Average Primary Investigator Compensation by Phase
75 Figure 2.44: Musculoskeletal: Average Number of Total Site Fees by Phase
76 Figure 2.45: Musculoskeletal: Average Number of Investigators Per Site by Phase
76 Figure 2.46: Musculoskeletal: Average Primary Investigator Compensation by Phase
77 Figure 2.47: Oncology: Average Number of Total Site Fees by Phase
77 Figure 2.48: Oncology: Average Number of Investigators Per Site by Phase
78 Figure 2.49: Oncology: Average Primary Investigator Compensation by Phase
78 Figure 2.50: Respiratory: Average Number of Total Site Fees by Phase
79 Figure 2.51: Respiratory: Average Number of Investigators Per Site by Phase
79 Figure 2.52: Respiratory: Average Primary Investigator Compensation by Phase
80 Figure 2.53: Women’s Health: Average Number of Total Site Fees by Phase
80 Figure 2.54: Women’s Health: Average Number of Investigators Per Site by Phase
81 Figure 2.55: Women’s Health: Average Primary Investigator Compensation by Phase
81 Figure 2.56: Medical Devices: Average Number of Total Site Fees by Phase
82 Figure 2.57: Medical Devices: Average Number of Investigators Per Site by Phase
82 Figure 2.58: Medical Devices: Average Primary Investigator Compensation by Phase
82 Investigator Compensation: Investigator Data
86 Figure 3.1: Percentage of Investigators Involved in Each Type of Clinical Trial
86 Figure 3.2: Number of Trials That an Average Investigator is Currently Leading by Category
87 Figure 3.3: Average Number of Companies that Investigators Have Run Trials for by Years
88 Figure 3.4: Years of Experience by Investigator Type
89 Figure 3.5: Percentage of Investigators Who Deliver Speeches
90 Figure 3.6: Number of Speeches Delivered in the Last Year by Investigator Type
91 Figure 3.7: Number of Articles Authored and Published by Investigator Type
92 Figure 3.8: Average Per-Site Total Fees by Phase
93 Figure 3.9: Average Primary Investigator Hours by Phase
94 Figure 3.10: Average Primary Investigator Hourly Rates by Phase
95 Figure 3.11: Average Percentage of Total Fees Allocated to the Primary Investigator by Phase
96 Figure 3.12: Average Percentage of Total Fees Allocated to the Secondary Investigator by Phase
97 Figure 3.13: Average Primary Investigator Total Compensation by Phase
98 Figure 3.14: Average Primary Investigator Compensation Per Patient by Phase
99 Figure 3.15: Average Secondary Investigator Total Compensation by Phase
100 Figure 3.16: Average Secondary Investigator Compensation Per Patient by Phase
101 Figure 3.17: Years of Experience Necessary for Significant Difference in Primary
101 Investigator Compensation By Phase
102 Figure 3.18: Average Compensation for Phase 1 Primary Investigators based on Years of Experience
103 Figure 3.19: Average Compensation for Phase 2 Primary Investigators based on Years of Experience
103 Figure 3.20: Average Compensation for Phase 3a Primary Investigators based on
103 Years of Experience
104 Figure 3.21: Average Compensation for Phase 3b Primary Investigators based on Years of Experience
104 Figure 3.22: Average Compensation for Phase 4 Primary Investigators based on Years of Experience